Abingdon Health PLC
25 September 2026
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Official opening of manufacturing hub in the US
York, UK and Madison, WI, USA, 25 September 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and provider of regulatory services for rapid diagnostic tests and med-tech, announces the official opening yesterday of its new manufacturing hub at the Company’s facility at University Research Park in Madison, Wisconsin. The opening is an important milestone in the Company’s continued expansion and investment in its US operations.
The official ribbon-cutting event was attended by Congressman Mark Pocan, representing Wisconsin’s 2nd Congressional District; Madison Mayor Satya Rhodes-Conway; WEDC Secretary John Miller; various representatives from the Wisconsin State Legislature; leaders of Wisconsin’s biohealth industry; as well as representatives from the Company.
Chris Yates (Left foreground) with Tanya Quint, Site Lead, Abingdon Health USA Inc. (Centre left)
and Mayor Satya Rhodes-Conway (Centre right)
The new manufacturing facility represents a significant step forward for the Company’s US operations, providing Abingdon Health with the infrastructure and capacity to expand its US footprint and respond to growing demand for high-quality, rapidly deployable diagnostic testing solutions developed and ‘Made in the USA’.
Left to right (foreground): Chris Yates, Wisconsin Assembly Representative Lisa Subeck, Congressman Mark Pocan and WEDC Secretary John Miller (with Jose Rodriguez from the Office of Wisconsin Senate minority leader Dianne Hesselbein in the background between Lisa Subeck and Mark Pocan)
Chris Yates, President of Abingdon Health USA and Chief Commercial Officer of Abingdon Health plc, commented:“The opening of our Madison manufacturing hub is a significant milestone for Abingdon Health USA that enables us to offer a more comprehensive and integrated “end to end” CDMO solution for our US customers, paving the way for continued growth in the biggest med-tech market in the world.
“We were delighted to welcome Representative Mark Pocan, Mayor Satya Rhodes-Conway, WEDC Secretary John Miller and other legislative and industry leaders to the ribbon-cutting ceremony. Their support throughout our journey is recognition of the importance of high-quality, domestic diagnostics manufacturing for the United States as well our investment in Madison and its community.”
Enquiries:
|
Abingdon Health plc |
||
|
Chris Hand,ExecutiveChairman
|
Via Walbrook PR | |
|
Tom Hayes, CFO
|
| |
|
|
| |
|
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser) |
Tel:+44 (0)20 7220 0500 | |
|
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales) |
| |
|
|
| |
|
Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 orabingdon@walbrookpr.com | |
|
Paul McManus/Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About Abingdon Health
Abingdon HealthGroupis a leading med-tech contract service provider offering its services to an international customer base.
The Group’s CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory strategy support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company’s subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.
Founded in 2008,Abingdon Healthis headquartered inYork, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health'sbrochuresoutlines the comprehensive support the Group can now provide to its international customers.For more information visit:www.abingdonhealth.com.
LEI - 213800XFI4WV3FBILO20
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.